Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers.
about
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.Tofacitinab in renal transplantation.Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials.Intracellular signal pathways: potential for therapies.Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trialTofacitinib.A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease.Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers.Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.
P2860
Q34084020-FF70B336-FE6C-4E37-AC3C-846CE0D44778Q34357184-909DCCAD-943E-4108-A717-ECD3D2C58323Q34454531-1679E5E7-9131-4F54-947F-6EBFCA7F9302Q34551138-E239015A-AC7D-42FF-B8FA-6AC040D9194EQ35654020-2098AC52-72A7-4751-BDFC-0757E5A3ECC1Q37340011-EF0BE2E8-765C-46DA-B848-F804637BF324Q38097494-8DC6996B-06B4-4BCC-820F-A22D9D1E1873Q41931494-9622A7C5-4509-4BC1-AFC2-46768155775EQ46410819-0157AACF-BCFF-4674-91B7-7E882181D4E0Q49232396-DF9C67FB-FEC1-4359-9ED2-50AF933EED1EQ53109200-90A56CCC-A28E-4A7B-A270-4D3C3E4CC2ABQ53111660-8F41DD15-CCFA-400B-A9B1-8C897D05EDADQ54312411-C10DA346-1943-4418-911A-A6B7E9FF92D4
P2860
Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Effect of CP-690,550, an orall ...... n in healthy adult volunteers.
@en
Effect of CP-690,550, an orall ...... n in healthy adult volunteers.
@nl
type
label
Effect of CP-690,550, an orall ...... n in healthy adult volunteers.
@en
Effect of CP-690,550, an orall ...... n in healthy adult volunteers.
@nl
prefLabel
Effect of CP-690,550, an orall ...... n in healthy adult volunteers.
@en
Effect of CP-690,550, an orall ...... n in healthy adult volunteers.
@nl
P2093
P2860
P356
P1476
Effect of CP-690,550, an orall ...... n in healthy adult volunteers.
@en
P2093
Courtney Cannon
David Gruben
Nervin Lawendy
Sriram Krishnaswami
Suzanne Swan
P2860
P304
P356
10.1177/0091270008330982
P577
2009-04-01T00:00:00Z